All

All
Insight
Research Services
Preclinical CRO
Animal Resource Bank

Comprehensive Experimental Services

Supporting scientific research innovation and drug development

Aniphe BioLab focuses on integrated preclinical biopharmaceutical services. Leveraging cutting-edge academic collaborations and high‑impact translational research—such as those published in Nature Communications—the company has established a comprehensive disease‑model platform spanning metabolic, neurodegenerative, cardiovascular, and natural aging disorders. It is equipped with CRISPR‑based in vitro, in vivo, and in silico screening and gene‑editing platforms, integrates small‑animal imaging with multi‑omics profiling capabilities, and offers end‑to‑end services for drug discovery, pharmacodynamics, pharmacokinetics, and toxicology–safety evaluation. Furthermore, the company extends its support to the entire R&D pipeline, including CMC and analytical testing, providing a closed‑loop, full‑process development ecosystem.

10000 +

Customized animal models

1300 +

Professional Technical Team

5000 +

SPF-grade experimental facility

100 +

Partner Universities and Research Institutions

Psychiatric & neurological disease models

Publish an article

2026-10-29

Naming Genetically Engineered Mice (Part II): From Being Understandable to Being Written Correctly

2026-10-29

How should a multi-disease composite mouse model be constructed? Let’s take a look at the CKM approach.

2026-08-12

2026 CKM Guidelines Released: Chronic Diseases Enter the Era of Integrated Cardiorenal-Metabolic Management—It’s Time to Rethink Animal Models

2026-08-12

A Guide to Safe Mouse Handling | Manual on Mouse Transport Protocols and Troubleshooting

Aniphe BioLabtechnology’s Four Core Advantages

High‑level academic endorsement and technology transfer

We maintain long-term, in-depth professional collaborations with world‑class academic research teams. For example, in a high‑impact study on the mechanisms of aging—specifically, PKM2 protein aggregates—published by a research team from Peking University in the prestigious international journal Nature Communications, Aniphe BioLab played a pivotal role as a key provider of experimental materials and technical services, demonstrating its industry‑leading capabilities in translating academic findings into practical applications and delivering robust technological support.

Specialized Disease Models and a Comprehensive Characterization Platform

We have established deep expertise in the preclinical disease‑modeling space, with an industry‑leading portfolio of models and a comprehensive suite of cutting‑edge small‑animal imaging techniques—including high‑resolution ultrasound—particularly in metabolic disorders (MASH/NASH, obesity), neurodegenerative diseases (AD, PD), cardiovascular conditions (pulmonary arterial hypertension, myocardial infarction), and natural aging.

CRISPR Screening and Genome Editing at the Cutting Edge of Technology

Keeping pace with the international forefront of high-throughput target discovery, Aniphe BioLab has established a three‑pronged CRISPR screening platform—encompassing in vitro, in vivo, and in silico (computational) approaches—alongside customized gene‑editing mouse services, providing comprehensive coverage from high‑throughput target identification and validation to mechanistic elucidation.

End-to-end, one-stop integrated service system

By addressing the pain points of traditional, fragmented outsourcing, we have established an end-to-end closed-loop spanning target identification, cell‑based assays, mouse models, small‑animal ultrasound imaging, drug metabolism studies, pathological analyses, and multi‑omics profiling, offering clients comprehensive, customized, and highly specialized solutions across the entire R&D pipeline.

Experimental results

Early Drug Discovery and Screening

(Drug Discovery)

It can precisely identify and optimize “seed” compounds or biomacromolecules with development potential for clients. Target validation: Leveraging cutting-edge gene-editing technologies such as CRISPR/Cas9 and RNAi, we establish customized cell models to rigorously assess the feasibility of specific genes or proteins as therapeutic targets.

Learn more →

Pharmacodynamics and Disease Model Research

(Pharmacodynamics & Models)

Verifying a drug’s efficacy is the cornerstone of preclinical evaluation. Aniphe BioLab boasts an extensive library of model mice and extensive expertise in establishing inducible disease models: In Vivo Animal Model Repository: Genetically engineered mouse models: We offer a comprehensive portfolio, including 5xFAD, APP/PS1, various whole-body or conditional knockout (KO/cKO) models, knock-in (KI) models, and humanized mouse models.

Learn more →

Pharmacokinetic study

(Pharmacokinetics, PK/PD)

In-depth investigation of the dynamic processes of drug absorption, distribution, metabolism, and excretion (ADME) within living organisms. In vivo PK studies: Support multiple administration routes, including intravenous (IV), oral (PO), subcutaneous (SC), and intraperitoneal (IP), enabling high‑precision plasma concentration monitoring and pharmacokinetic analysis in both rodent (large and small mice) and non‑rodent species. Tissue distribution and barrier penetration: Characterize the drug’s organ‑specific distribution in vivo, with a particular focus on assessing its ability to cross the blood–brain barrier (BBB), thereby providing critical data for neurological drug development. Excretion studies and metabolite profiling: Collect urine, feces, and bile to conduct precise analyses of drug excretion ratios and metabolite profiles. Early in vitro ADME screening: Offer assays for plasma protein binding, metabolic stability, CYP450 enzyme inhibition and induction, as well as Caco‑2 permeability testing.

Learn more →

Safety Assessment/Toxicological Studies

(Toxicology & Safety Assessment)

Conduct rigorous assessments of a drug’s safety to provide compliant safety evaluation support for IND submissions. Single‑dose and repeated‑dose toxicity studies: Thoroughly evaluate both acute and chronic toxicological responses in animals, accurately defining the drug’s safety margin and identifying target organs of toxicity.

Learn more →

Pharmaceutical Research and Analytical Testing Services

(CMC & Analytical Services)

As the foundational infrastructure underpinning all experiments, Aniphe BioLab has established a high‑standard testing and analytical platform to ensure the compliance and reliability of experimental data. Cell Biology and Routine Assays: Proficiently performs a comprehensive suite of molecular biology assays, including flow cytometry (FACS/MACS), ELISA, Western blotting, qPCR, and more.

Learn more →

End-to-end service support

(End-to-End Support)

· End-to-end services, from conceptual design to model delivery · Standardized project management and a well-defined roadmap · Comprehensive implementation records and compliance reports · Long-term partnerships and ongoing technical support

Learn more →